Abstract
Squamous cell carcinoma of the penis is a rare cancer, with inguinal lymph node metastasis being the most important prognostic factor for the disease. Loco-regionally advanced disease has traditionally been managed by surgery and postoperative radiotherapy, but a multimodal approach to treatment has evolved over the past 20 years. The latest evidence suggests that neoadjuvant platinum-based triplet systemic chemotherapy can provide good outcomes for men with bulky or initially unresectable nodal metastases, with response rates as high as 65 %, enabling consolidation surgery in a fair proportion of men and achieving pathologic complete responses in 10–16 %. Nevertheless, survival outcomes for men with locally advanced or metastatic disease are moderate, with a 5-year overall survival of 50 % being the best outlook for men who respond to neoadjuvant chemotherapy, which represents an improvement on historical survival rates. The past few years have seen greater emphasis on determining the effect of human papillomavirus infection in penile cancer and outlining prognostic cohorts, together with investigation of targeted therapy, mainly for metastatic disease. It is hoped that multi-institutional collaboration within the International Rare Cancers Initiative will provide the first randomized data on men with locally advanced or metastatic disease, and outline novel treatment paradigms of how the integration of systemic chemotherapy, radiotherapy, surgery, and targeted therapy can be effectively used in a multimodal manner.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.
Goodman MT, Hernandez BY, Shvetsov YB. Demographic and pathologic differences in the incidence of invasive penile cancer in the United States, 1995–2003. Cancer Epidemiol Biomarkers Prev. 2007;16(9):1833–9. [Research Support, N.I.H., Extramural Research Support, U.S. Gov’t, P.H.S.].
Ravi R. Correlation between the extent of nodal involvement and survival following groin dissection for carcinoma of the penis. Br J Urol. 1993;72(5 Pt 2):817–9.
Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350(19):1945–52. [Clinical Trial Comparative Study Multicenter Study Randomized Controlled Trial Research Support, U.S. Gov’t, P.H.S.].
Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB 3rd, Thomas CR Jr., et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008;299(16):1914–21. [Clinical Trial, Phase III Comparative Study Multicenter Study Randomized Controlled Trial Research Support, N.I.H., Extramural].
Montana GS, Thomas GM, Moore DH, Saxer A, Mangan CE, Lentz SS, et al. Preoperative chemo-radiation for carcinoma of the vulva with N2/N3 nodes: a gynecologic oncology group study. Int J Radiat Oncol Biol Phys. 2000;48(4):1007–13. [Clinical Trial Randomized Controlled Trial Research Support, U.S. Gov’t, P.H.S.].
Leijte JA, Kerst JM, Bais E, Antonini N, Horenblas S. Neoadjuvant chemotherapy in advanced penile carcinoma. Eur Urol. 2007;52(2):488–94.
Hakenberg OW, Nippgen JB, Froehner M, Zastrow S, Wirth MP. Cisplatin, methotrexate and bleomycin for treating advanced penile carcinoma. BJU Int. 2006;98(6):1225–7.
Pond GR, Milowsky MI, Kolinsky MP, Eigl BJ, Necchi A, Harshman LC, et al. Concurrent chemoradiotherapy for men with locally advanced penile squamous cell carcinoma. Clin Genitourin Cancer. 2014;12(6):440–6.
Pagliaro LC, Williams DL, Daliani D, Williams MB, Osai W, Kincaid M, et al. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol. 2010;28(24):3851–7. [Clinical Trial, Phase II Research Support, N.I.H., Extramural].
Theodore C, Skoneczna I, Bodrogi I, Leahy M, Kerst JM, Collette L, et al. A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992). Ann Oncol. 2008;19(7):1304–7. [Clinical Trial, Phase II Multicenter Study Research Support, N.I.H., Extramural].
Djajadiningrat RS, Bergman AM, van Werkhoven E, Vegt E, Horenblas S. Neoadjuvant taxane-based combination chemotherapy in patients with advanced penile cancer. Clin Genitourin Cancer. 2015;13(1):44–9.
Hakenberg OW, Wirth MP. Issues in the treatment of penile carcinoma. A short review. Urol Int. 1999;62(4):229–33. [Review].
Pizzocaro G, Piva L, Bandieramonte G, Tana S. Up-to-date management of carcinoma of the penis. Eur Urol. 1997;32(1):5–15. [Research Support, Non-U.S. Gov’t Review].
Leijte JA, Kirrander P, Antonini N, Windahl T, Horenblas S. Recurrence patterns of squamous cell carcinoma of the penis: recommendations for follow-up based on a two-centre analysis of 700 patients. Eur Urol. 2008;54(1):161–8.
Ficarra V, Akduman B, Bouchot O, Palou J, Tobias-Machado M. Prognostic factors in penile cancer. Urology. 2010;76(2 Suppl 1):S66–73. [Review].
Slaton JW, Morgenstern N, Levy DA, Santos Jr MW, Tamboli P, Ro JY, et al. Tumor stage, vascular invasion and the percentage of poorly differentiated cancer: independent prognosticators for inguinal lymph node metastasis in penile squamous cancer. J Urol. 2001;165(4):1138–42.
Pizzocaro G, Piva L. Adjuvant and neoadjuvant vincristine, bleomycin, and methotrexate for inguinal metastases from squamous cell carcinoma of the penis. Acta Oncol. 1988;27(6b):823–4. [Research Support, Non-U.S. Gov’t].
Nicolai N, Sangalli LM, Necchi A, Giannatempo P, Paganoni AM, Colecchia M, et al. A combination of cisplatin and 5-fluorouracil with a taxane in patients who underwent lymph node dissection for nodal metastases from squamous cell carcinoma of the penis: treatment outcome and survival analyses in neoadjuvant and adjuvant settings. Clin Genitourin Cancer. 2016;14(4):323–30.
Noronha V, Patil V, Ostwal V, Tongaonkar H, Bakshi G, Prabhash K. Role of paclitaxel and platinum-based adjuvant chemotherapy in high-risk penile cancer. Urol Ann. 2012;4(3):150–3.
Sharma P, Djajadiningrat R, Zargar-Shoshtari K, Catanzaro M, Zhu Y, Nicolai N, et al. Adjuvant chemotherapy is associated with improved overall survival in pelvic node-positive penile cancer after lymph node dissection: a multi-institutional study. Urol Oncol. 2015;33(11):496.e17–23.
Hakenberg OW, Comperat EM, Minhas S, Necchi A, Protzel C, Watkin N. EAU guidelines on penile cancer: 2014 update. Eur Urol. 2015;67(1):142–50. [Practice Guideline].
Clark PE, Spiess PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, et al. Penile cancer: clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2013;11(5):594–615. [Practice Guideline].
Burt LM, Shrieve DC, Tward JD. Stage presentation, care patterns, and treatment outcomes for squamous cell carcinoma of the penis. Int J Radiat Oncol Biol Phys. 2014;88(1):94–100.
Chen MF, Chen WC, Wu CT, Chuang CK, Ng KF, Chang JT. Contemporary management of penile cancer including surgery and adjuvant radiotherapy: an experience in Taiwan. World J Urol. 2004;22(1):60–6.
Franks KN, Kancherla K, Sethugavalar B, Whelan P, Eardley I, Kiltie AE. Radiotherapy for node positive penile cancer: experience of the Leeds teaching hospitals. J Urol. 2011;186(2):524–9. [Research Support, Non-U.S. Gov’t].
Pandey D, Mahajan V, Kannan RR. Prognostic factors in node-positive carcinoma of the penis. J Surg Oncol. 2006;93(2):133–8.
Novara G, Galfano A, De Marco V, Artibani W, Ficarra V. Prognostic factors in squamous cell carcinoma of the penis. Nat Clin Pract Urol. 2007;4(3):140–6. [Review].
Haas GP, Blumenstein BA, Gagliano RG, Russell CA, Rivkin SE, Culkin DJ, et al. Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: a Southwest Oncology Group study. J Urol. 1999;161(6):1823–5. [Clinical Trial Research Support, U.S. Gov’t, P.H.S.].
Bevan-Thomas R, Slaton JW, Pettaway CA. Contemporary morbidity from lymphadenectomy for penile squamous cell carcinoma: the M.D. Anderson Cancer Center Experience. J Urol. 2002;167(4):1638–42. [Comparative Study].
Dickstein RJ, Munsell MF, Pagliaro LC, Pettaway CA. Prognostic factors influencing survival from regionally advanced squamous cell carcinoma of the penis after preoperative chemotherapy. BJU Int. 2016;117(1):118–25.
Nicholson S, Hall E, Harland SJ, Chester JD, Pickering L, Barber J, et al. Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001). Br J Cancer. 2013;109(10):2554–9. [Clinical Trial, Phase II Multicenter Study Research Support, Non-U.S. Gov’t].
Longpre MJ, Lange PH, Kwon JS, Black PC. Penile carcinoma: lessons learned from vulvar carcinoma. J Urol. 2013;189(1):17–24. [Comparative Study Review].
Ravi R, Chaturvedi HK, Sastry DV. Role of radiation therapy in the treatment of carcinoma of the penis. Br J Urol. 1994;74(5):646–51.
Chhabra A, Schwartz D, Leaf A, Karanikolas N, Weiss JP, Schreiber D. Neoadjuvant concurrent chemoradiation for curative treatment of penile squamous cell carcinoma. Case Rep Oncol Med. 2014;2014:479376.
Eliason M, Bowen G, Bowen A, Hazard L, Samlowski W. Primary treatment of verrucous carcinoma of the penis with fluorouracil, cis-diamino-dichloro-platinum, and radiation therapy. Arch Dermatol. 2009;145(8):950–2. [Case Reports Letter].
Backes DM, Kurman RJ, Pimenta JM, Smith JS. Systematic review of human papillomavirus prevalence in invasive penile cancer. Cancer Causes Control. 2009;20(4):449–57. [Research Support, Non-U.S. Gov’t Review].
Flaherty A, Kim T, Giuliano A, Magliocco A, Hakky TS, Pagliaro LC, et al. Implications for human papillomavirus in penile cancer. Urol Oncol. 2014;32(1):53.e1–8. [Review].
Bezerra AL, Lopes A, Santiago GH, Ribeiro KC, Latorre MR, Villa LL. Human papillomavirus as a prognostic factor in carcinoma of the penis: analysis of 82 patients treated with amputation and bilateral lymphadenectomy. Cancer. 2001;91(12):2315–21. [Research Support, Non-U.S. Gov’t].
Lont AP, Kroon BK, Horenblas S, Gallee MP, Berkhof J, Meijer CJ, et al. Presence of high-risk human papillomavirus DNA in penile carcinoma predicts favorable outcome in survival. Int J Cancer. 2006;119(5):1078–81.
Chaux A, Munari E, Katz B, Sharma R, Lecksell K, Cubilla AL, et al. The epidermal growth factor receptor is frequently overexpressed in penile squamous cell carcinomas: a tissue microarray and digital image analysis study of 112 cases. Hum Pathol. 2013;44(12):2690–5. [Research Support, Non-U.S. Gov’t].
Necchi A, Nicolai N, Colecchia M, Catanzaro M, Torelli T, Piva L, et al. Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis. J Clin Oncol. 2011;29(22):e650–2. [Case Reports].
Brown A, Ma Y, Danenberg K, Schuckman AK, Pinski JK, Pagliaro LC, et al. Epidermal growth factor receptor-targeted therapy in squamous cell carcinoma of the penis: a report of 3 cases. Urology. 2014;83(1):159–65. [Case Reports Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t].
Carthon BC, Ng CS, Pettaway CA, Pagliaro LC. Epidermal growth factor receptor-targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis. BJU Int. 2014;113(6):871–7. [Research Support, N.I.H., Extramural].
Zhu Y, Li H, Yao XD, Zhang SL, Zhang HL, Shi GH, et al. Feasibility and activity of sorafenib and sunitinib in advanced penile cancer: a preliminary report. Urol Int. 2010;85(3):334–40.
Keat N, Law K, Seymour M, Welch J, Trimble T, Lascombe D, et al. International rare cancers initiative. Lancet Oncol. 2013;14(2):109–10.
Nicholson S, Kayes O, Minhas S. Clinical trial strategy for penis cancer. BJU Int. 2014;113(6):852–3.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media LLC
About this chapter
Cite this chapter
Ravi, P., Pagliaro, L.C. (2017). Multimodal Approach to Locally Advanced and Metastatic Penile Cancer. In: Spiess, P. (eds) Penile Cancer. Current Clinical Urology. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-6679-0_8
Download citation
DOI: https://doi.org/10.1007/978-1-4939-6679-0_8
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-6677-6
Online ISBN: 978-1-4939-6679-0
eBook Packages: MedicineMedicine (R0)